📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. (2020)

First Author: Zumla A

Attributed to: A GMP cell therapy facility to test cell based therapies funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ijid.2020.05.040

PubMed Identifier: 32425638

Publication URI: http://europepmc.org/abstract/MED/32425638

Type: Journal Article/Review

Volume: 96

Parent Publication: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

ISSN: 1201-9712